LONDON--(BUSINESS WIRE)--Sep 15, 2025--
ReBound Returns, the global leader in returns management, has been named a Premier Partner of Shopify, the all-in-one commerce platform powering millions of businesses worldwide. This expanded partnership brings a seamless, enterprise-grade returns solution to Shopify merchants, empowering brands to streamline operations, reduce costs, elevate customer satisfaction, and improve customer retention at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915533038/en/
Through this partnership, Shopify merchants immediately gain access to ReBound’s fully managed, end-to-end returns system. The solution supports the entire post-purchase journey, from initiation and to shipping with local carriers, processing in ReBound returns centres, all the way to the items’ final destination. On average, merchants using ReBound have seen 30% higher customer retention thanks to smoother, customer-centric return experiences.
As a Premier Partner, ReBound offers a unified returns solution for both e-commerce and retail returns, integrating across all customer touchpoints. Merchants can leverage access to over 300 global carriers and more than 40 regional return hubs, enabling early refunds and fast, sustainable returns around the globe.
Shopify customers using ReBound can get significant business impact, including a 25% increase in Net Promoter Score (NPS), a 50% higher checkout conversion via Shop Pay, and a 40% reduction in customer service requests.
Andrew Hill, New Business Director at ReBound Returns commented: “At ReBound, we’re committed to transforming returns management into a strategic advantage. By expanding our collaboration with Shopify as a Premier Partner, we’re deepening our ability to deliver smarter, more scalable, and more sustainable returns solutions for the world’s leading brands. This partnership strengthens our mission to enhance customer satisfaction and streamline operations by providing a superior returns experience across every channel.”
ReBound currently supports clients worldwide , including leading Shopify brands in fashion, lifestyle, and consumer electronics. Its system is specifically built for enterprise retailers, combining powerful returns technology with logistics enabling features like exchanges, refund triggers, end-to-end tracking, fraud protection, and much more.
Notes to Editors
About ReBound Returns. ReBound (part of Reconomy) is the leading global returns management specialist, enabling easy omnichannel returns for brands and consumers. By combining integrated returns software with an extensive logistics network, ReBound optimizes and manages the entire returns lifecycle so clients can focus on their core business.
https://www.reboundreturns.com/
ReBound Returns
VIENNA--(BUSINESS WIRE)--Dec 7, 2025--
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67 th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/
ROP-ET and BESREMI PASS
One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive therapies 1.
The other investigation, the BESREMi-PASS study, looked at how the medicine performs in everyday clinical practice among people with polycythemia vera (PV). PV is a rare cancer of the blood-building stem cells in the bone marrow resulting in a chronic increase of red blood cells, white blood cells and platelets.
Solutions for unmet medical need
Both studies provide new insights into how ropeginterferon alfa-2b may help people living with these chronic blood cancers.
Martin Steinhart, CEO of AOP Health, concludes: “AOP Health was founded to address unmet patient needs in rare indications. Our continued investment in research and development is a testament to that commitment, resulting in new findings that we are now proud to share with the scientific community at ASH.”
About Ropeginterferon alfa-2b
Ropeginterferon alfa-2b is the first interferon approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythaemia vera without symptomatic enlarged spleen.
Ropeginterferon alfa-2b is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. It is designed to be self-administered subcutaneously with a pre-filled pen.
About AOP Health
AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company’s actions. (aop-health.com)
1 Kiladjian JJ, Marin FF, Al-Ali HK, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Annals of Hematology. 2024 Mar 4:1-2.
Needs. Science. Trust.
AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group
Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart
